EyePoint Pharmaceuticals launches Yutiq in US

Oxford Biomedica & Santen to develop gene therapy for inherited retinal disease
Credit: Shutterstock.com/ Romaset

EyePoint Pharmaceuticals has recently launched its Yutiq product in the US.

Yutiq is an FDA-approved, three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

The launch was paired with EyePoint Assist, a programme to ensure access to Yutiq for eligible patients in need of financial assistance.

Yutiq utilises EyePoint’s Durasert drug delivery technology and is an intravitreal micro-insert containing 0.18 mg of fluocinolone acetonide, designed to release consistently for up to 36 months.

It is supplied in a sterile single-dose preloaded applicator that can be administered in the physician’s office.

In Phase 3 clinical trials, Yutiq significantly reduced the rate of recurrent uveitis flares versus sham, and the most common adverse reactions reported were cataract development and increase in intraocular pressure.

Nancy Lurker, President and CEO of EyePoint Pharmaceuticals, said: “Yutiq is the first FDA-approved fluocinolone acetonide micro-insert to address this serious condition that is the third leading cause of blindness in the country.”